<table border="1" id="table_5" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 5. Established and Other Potentially Significant Drug Interactions</caption>
<col span="1" width="20%"></col>
<col span="1" width="20%"></col>
<col span="1" width="59%"></col>
<tbody>
<tr>
<td>
<content stylecode="bold">Concomitant Drug Class:</content>
<br/>
<content stylecode="bold">Drug Name</content>
</td>
<td>
<content stylecode="bold">Effect on Concentration of Ritonavir or Concomitant Drug</content>
</td>
<td>
<content stylecode="bold">Clinical Comment</content>
</td>
</tr>
<tr>
<td> <content stylecode="italics">
<content stylecode="bold">HIV-Antiviral Agents</content>
</content>  </td>
</tr>
<tr>
<td>HIV-1 Protease Inhibitor:<br/>atazanavir</td>
<td>When co-administered with reduced doses of atazanavir and ritonavir<br/>↑ atazanavir (↑ AUC, ↑ C<sub>max</sub>, ↑ C<sub>min</sub>)</td>
<td>Atazanavir plasma concentrations achieved with atazanavir 300 mg once daily and ritonavir 100 mg once daily are higher than those achieved with atazanavir 400 mg once daily. See the complete prescribing information for Reyataz<sup>®</sup> (atazanavir) for details on co-administration of atazanavir 300 mg once daily  with ritonavir 100 mg once daily.</td>
</tr>
<tr>
<td>HIV-1 Protease Inhibitor:<br/>darunavir</td>
<td>When co-administered with reduced doses of ritonavir<br/>↑ darunavir (↑ AUC, ↑ C<sub>max</sub>, ↑ C<sub>min</sub>)</td>
<td>See the complete prescribing information for Prezista<sup>®</sup> (darunavir) for details on co-administration of darunavir 600 mg twice daily with ritonavir 100 mg twice daily or darunavir 800 mg once daily with ritonavir 100 mg once daily.  </td>
</tr>
<tr>
<td>HIV-1 Protease Inhibitor:<br/>fosamprenavir</td>
<td>When co-administered with reduced doses of ritonavir<br/> ↑ amprenavir (↑ AUC, ↑ C<sub>max</sub>, ↑ C<sub>min</sub>)</td>
<td>See the complete prescribing information for Lexiva<sup>®</sup> (fosamprenavir) for details on co-administration of fosamprenavir 700 mg twice daily with ritonavir 100 mg twice daily, fosamprenavir 1400 mg once daily with ritonavir 200 mg once daily or fosamprenavir 1400 mg once daily with ritonavir 100 mg once daily.</td>
</tr>
<tr>
<td>HIV-1 Protease Inhibitor:<br/>indinavir</td>
<td>When co-administered with reduced doses of indinavir and ritonavir<br/>↑ indinavir  (↔ AUC, ↓ C<sub>max</sub>, ↑ C<sub>min</sub>)</td>
<td>Alterations in concentrations are noted when reduced doses of indinavir are co-administered with NORVIR.<br/>Appropriate doses for this combination, with respect to efficacy and safety, have not been established.</td>
</tr>
<tr>
<td>HIV-1 Protease Inhibitor:<br/>saquinavir</td>
<td>When co-administered with reduced doses of ritonavir<br/>↑ saquinavir <br/>(↑ AUC, ↑ C<sub>max</sub>, ↑ C<sub>min</sub>)</td>
<td>See the complete prescribing information for Invirase<sup>®</sup> (saquinavir) for details on co-administration of saquinavir 1000 mg twice daily with ritonavir 100 mg twice daily.<br/>Saquinavir/ritonavir should not be given together with rifampin, due to the risk of severe hepatotoxicity (presenting as increased hepatic transaminases) if the three drugs are given together.</td>
</tr>
<tr>
<td>HIV-1 Protease Inhibitor:<br/>tipranavir</td>
<td>When co-administered with reduced doses of ritonavir<br/> ↑ tipranavir (↑ AUC, ↑ C<sub>max</sub>, ↑ C<sub>min</sub>)</td>
<td>See the complete prescribing information for Aptivus<sup>®</sup> (tipranavir) for details on co-administration of tipranavir 500 mg twice daily with ritonavir 200 mg twice daily. There have been reports of clinical hepatitis and hepatic decompensation including some fatalities.  All patients should be followed closely with clinical and laboratory monitoring, especially those with chronic hepatitis B or C co-infection, as these patients have an increased risk of hepatotoxicity. Liver function tests should be performed prior to initiating therapy with tipranavir/ritonavir, and frequently throughout the duration of treatment.</td>
</tr>
<tr>
<td>Non-Nucleoside Reverse Transcriptase Inhibitor:<br/>delavirdine</td>
<td>↑ ritonavir (↑AUC, ↑C<sub>max</sub>, ↑ C<sub>min</sub>)</td>
<td>Appropriate doses of this combination with respect to safety and efficacy have not been established.</td>
</tr>
<tr>
<td>HIV-1 CCR5 – antagonist: maraviroc</td>
<td>↑ maraviroc</td>
<td>Concurrent administration of maraviroc with ritonavir will increase plasma levels of maraviroc.  For specific dosage adjustment recommendations, please refer to the complete prescribing information for Selzentry<sup>®</sup>  (maraviroc).</td>
</tr>
<tr>
<td>Integrase Inhibitor: Raltegravir</td>
<td>↓ raltegravir</td>
<td>The effects of ritonavir on raltegravir with ritonavir dosage regimens greater than 100 mg twice daily have not been evaluated, however raltegravir concentrations may be decreased with ritonavir coadministration.</td>
</tr>
<tr>
<td>
<content stylecode="italics">
<content stylecode="bold">Other Agents</content>
</content>
</td>
</tr>
<tr>
<td>Analgesics, Narcotic:<br/>tramadol, propoxyphene</td>
<td> </td>
<td>A dose decrease may be needed for these drugs when co-administered with ritonavir.</td>
</tr>
<tr>
<td>Anesthetic:<br/>meperidine</td>
<td>↓ meperidine/ ↑ normeperidine (metabolite)</td>
<td>Dosage increase and long-term use of meperidine with ritonavir are not recommended due to the increased concentrations of the metabolite normeperidine which has both analgesic activity and CNS stimulant activity (e.g., seizures).</td>
</tr>
<tr>
<td>Antialcoholics:<br/>disulfiram/ metronidazole</td>
<td> </td>
<td>Ritonavir formulations contain alcohol, which can produce disulfiram-like reactions when co-administered with disulfiram or other drugs that produce this reaction (e.g., metronidazole).</td>
</tr>
<tr>
<td>Antiarrhythmics:<br/>disopyramide, lidocaine, mexiletine</td>
<td>↑ antiarrhythmics</td>
<td>Caution is warranted and therapeutic concentration monitoring is recommended for antiarrhythmics when co-administered with ritonavir, if available.</td>
</tr>
<tr>
<td>Anticancer Agents: <br/>dasatinib, nilotinib,<br/>vincristine, vinblastine </td>
<td>↑ anticancer agents</td>
<td>Concentrations of these drugs may be increased when co-administered with ritonavir resulting in the potential for increased adverse events usually associated with these anticancer agents.  <br/>For vincristine and vinblastine, consideration should be given to temporarily withholding the ritonavir containing antiretroviral regimen in patients who develop significant hematologic or gastrointestinal side effects when ritonavir is administered concurrently with vincristine or vinblastine. Clinicians should be aware that if the ritonavir containing regimen is withheld for a prolonged period, consideration should be given to altering the regimen to not include a CYP3A or P-gp inhibitor in order to control HIV-1 viral load.<br/>A decrease in the dosage or an adjustment of the dosing interval of nilotinib and dasatinib may be necessary for patients requiring co-administration with strong CYP3A inhibitors such as NORVIR. Please refer to the nilotinib and dasatinib prescribing information for dosing instructions.</td>
</tr>
<tr>
<td>Anticoagulant:  <br/>warfarin</td>
<td>↓ R-warfarin<br/>↓↑ S-warfarin</td>
<td>Initial frequent monitoring of the INR during ritonavir and warfarin co-administration is indicated.</td>
</tr>
<tr>
<td>Anticoagulant: <br/>rivaroxaban</td>
<td>↑ rivaroxaban</td>
<td>Avoid concomitant use of rivaroxaban and ritonavir. Co-administration of ritonavir and rivaroxaban is expected to result in increased exposure of rivaroxaban which may lead to risk of increased bleeding.</td>
</tr>
<tr>
<td>Anticonvulsants:<br/>carbamazepine, clonazepam, ethosuximide</td>
<td>↑ anticonvulsants</td>
<td>Use with caution. A dose decrease may be needed for these drugs when co-administered with ritonavir and therapeutic concentration monitoring is recommended for these anticonvulsants, if available.</td>
</tr>
<tr>
<td>Anticonvulsants:<br/>divalproex, lamotrigine, phenytoin</td>
<td>↓ anticonvulsants</td>
<td>Use with caution. A dose increase may be needed for these drugs when co-administered with ritonavir and therapeutic concentration monitoring is recommended for these anticonvulsants, if available.</td>
</tr>
<tr>
<td>Antidepressants:<br/>nefazodone, <br/>selective serotonin <br/>reuptake inhibitors <br/>(SSRIs): e.g.<br/>fluoxetine,<br/>paroxetine,<br/>tricyclics: e.g.<br/>amitriptyline,<br/>nortriptyline</td>
<td>↑ antidepressants</td>
<td>A dose decrease may be needed for these drugs when co-administered with ritonavir.</td>
</tr>
<tr>
<td>Antidepressant:<br/>bupropion</td>
<td>↓ bupropion <br/>↓ active metabolite, hydroxybupropion</td>
<td>Concurrent administration of bupropion with ritonavir may decrease plasma levels of both bupropion and its active metabolite (hydroxybupropion).  Patients receiving ritonavir and bupropion concurrently should be monitored for an adequate clinical response to bupropion.  </td>
</tr>
<tr>
<td>Antidepressant:<br/>desipramine</td>
<td>↑ desipramine</td>
<td>Dosage reduction and concentration monitoring of desipramine is recommended.</td>
</tr>
<tr>
<td>Antidepressant:  trazodone</td>
<td>↑ trazodone</td>
<td>Concomitant use of trazodone and NORVIR increases plasma concentrations of trazodone.  Adverse events of nausea, dizziness, hypotension and syncope have been observed following co-administration of trazodone and NORVIR.  If trazodone is used with a CYP3A4 inhibitor such as ritonavir, the combination should be used with caution and a lower dose of trazodone should be considered.</td>
</tr>
<tr>
<td>Antiemetic:<br/>dronabinol</td>
<td>↑ dronabinol</td>
<td>A dose decrease of dronabinol may be needed when co-administered with ritonavir.</td>
</tr>
<tr>
<td>Antifungal:<br/>ketoconazole<br/>itraconazole<br/>voriconazole</td>
<td>↑ ketoconazole<br/>↑ itraconazole<br/>↓ voriconazole</td>
<td>
<paragraph id="p361303291426873251">High doses of ketoconazole or itraconazole (greater than 200 mg per day) are not recommended.<br/>
<br/>Co-administration of voriconazole and ritonavir doses of 400 mg every 12 hours or greater is contraindicated. Co-administration of voriconazole and ritonavir 100 mg should be avoided, unless an assessment of the benefit/risk to the patient justifies the use of voriconazole.</paragraph>
</td>
</tr>
<tr>
<td>Anti-gout: <br/>colchicine</td>
<td>↑ colchicine</td>
<td>
<paragraph id="p337994291426806633">Patients with renal or hepatic impairment should not be given colchicine with ritonavir.<br/>
<br/>
</paragraph>
<paragraph id="p358553291426806643">
<content stylecode="underline">Treatment of gout flares-co-administration of colchicine in patients on ritonavir:</content>
<br/>
<br/>
</paragraph>
<paragraph id="p453305291426806653">0.6 mg (one tablet) for one dose, followed by 0.3 mg (half tablet) one hour later. Dose to be repeated no earlier than three days.<br/>
<br/>
</paragraph>
<paragraph id="p453321291426806662">
<content stylecode="underline">Prophylaxis of gout flares-co-administration of colchicine in patients on ritonavir:</content>
<br/>
<br/>
</paragraph>
<paragraph id="p453341291426806670">If the original colchicine regimen was 0.6 mg twice a day, the regimen should be adjusted to 0.3 mg once a day.<br/>
<br/>
</paragraph>
<paragraph id="p453361291426806691">If the original colchicine regimen was 0.6 mg once a day, the regimen should be adjusted to 0.3 mg once every other day.<br/>
<br/>
</paragraph>
<paragraph id="p453381291426806698">
<content stylecode="underline">Treatment of familial Mediterranean fever (FMF)-co-administration of colchicine in patients on ritonavir:</content>
<br/>
<br/>
</paragraph>Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day).</td>
</tr>
<tr>
<td>Anti-infective:<br/>clarithromycin</td>
<td>↑ clarithromycin</td>
<td>For patients with renal impairment the following dosage adjustments should be considered:<br/>
<list id="l176921465" listtype="unordered">
<item>For patients with CL<sub>CR</sub> 30 to 60 mL per min the dose of clarithromycin should be reduced by 50%.</item>
<item>For patients with CL<sub>CR</sub> less than 30 mL per min the dose of clarithromycin should be decreased by 75%.</item>
</list>No dose adjustment for patients with normal renal function is necessary.</td>
</tr>
<tr>
<td>Antimycobacterial:<br/>rifabutin</td>
<td>↑ rifabutin and rifabutin metabolite</td>
<td>Dosage reduction of rifabutin by at least three-quarters of the usual dose of 300 mg per day is recommended (e.g., 150 mg every other day or three times a week).  Further dosage reduction may be necessary.</td>
</tr>
<tr>
<td>Antimycobacterial:<br/>rifampin</td>
<td>↓ ritonavir</td>
<td>May lead to loss of virologic response.  Alternate antimycobacterial agents such as rifabutin should be considered (see Antimycobacterial:  rifabutin, for dose reduction recommendations).</td>
</tr>
<tr>
<td>Antiparasitic:<br/>atovaquone	</td>
<td>↓ atovaquone</td>
<td>Clinical significance is unknown; however, increase in atovaquone dose may be needed.</td>
</tr>
<tr>
<td>Antiparasitic:<br/>quinine	</td>
<td>↑ quinine</td>
<td>A dose decrease of quinine may be needed when co-administered with ritonavir.</td>
</tr>
<tr>
<td>Antipsychotics:<br/>quetiapine</td>
<td>↑ quetiapine</td>
<td>
<paragraph id="p361403291427133410">
<content stylecode="underline">Initiation of NORVIR in patients taking quetiapine:</content>
<br/>
<br/>
</paragraph>
<paragraph id="p361315291427133579">Consider alternative antiretroviral therapy to avoid increases in quetiapine exposures. If coadministration is necessary, reduce the quetiapine dose to 1/6 of the current dose and monitor for quetiapine-associated adverse reactions. Refer to the quetiapine prescribing information for recommendations on adverse reaction monitoring.<br/>
<br/>
</paragraph>
<paragraph id="p455733291426808579">
<content stylecode="underline">Initiation of quetiapine in patients taking NORVIR:</content>
<br/>
<br/>
</paragraph>Refer to the quetiapine prescribing information for initial dosing and titration of quetiapine.</td>
</tr>
<tr>
<td>β-Blockers:<br/>metoprolol, timolol</td>
<td>↑ Beta-Blockers</td>
<td>Caution is warranted and clinical monitoring of patients is recommended.  A dose decrease may be needed for these drugs when co-administered with ritonavir.</td>
</tr>
<tr>
<td>Bronchodilator:<br/>theophylline</td>
<td>↓ theophylline</td>
<td>Increased dosage of theophylline may be required; therapeutic monitoring should be considered.</td>
</tr>
<tr>
<td>Calcium channel blockers:<br/>diltiazem, nifedipine, verapamil</td>
<td>↑ calcium channel blockers</td>
<td>Caution is warranted and clinical monitoring of patients is recommended.A dose decrease may be needed for these drugs when co-administered with ritonavir.</td>
</tr>
<tr>
<td>Digoxin	</td>
<td>↑ digoxin	</td>
<td>Concomitant administration of ritonavir with digoxin may increase digoxin levels.  Caution should be exercised when co-administering ritonavir with digoxin, with appropriate monitoring of serum digoxin levels.</td>
</tr>
<tr>
<td>Endothelin receptor antagonists: bosentan</td>
<td>↑ bosentan</td>
<td>
<paragraph id="p161523291426806738">
<content stylecode="underline">Co-administration of bosentan in patients on ritonavir:</content>
<br/>
<br/>
</paragraph>
<paragraph id="p161443291426806745">In patients who have been receiving ritonavir for at least 10 days, start bosentan at 62.5 mg once daily or every other day based upon individual tolerability.<br/>
<br/>
</paragraph>
<paragraph id="p453401291426806755">
<content stylecode="underline">Co-administration of ritonavir in patients on bosentan:</content>
<br/>
<br/>
</paragraph>
<paragraph id="p453421291426806761">Discontinue use of bosentan at least 36 hours prior to initiation of ritonavir.<br/>
<br/>
</paragraph>After at least 10 days following the initiation of ritonavir, resume bosentan at 62.5 mg once daily or every other day based upon individual tolerability.</td>
</tr>
<tr>
<td>HCV-Protease Inhibitor: simeprevir	 	</td>
<td>↑simeprevir</td>
<td>It is not recommended to co-administer ritonavir with simeprevir.</td>
</tr>
<tr>
<td>HMG-CoA Reductase Inhibitor:<br/>atorvastatin	<br/>rosuvastatin	</td>
<td>
<br/>↑ atorvastatin<br/>↑ rosuvastatin</td>
<td>Titrate atorvastatin and rosuvastatin dose carefully and use the lowest necessary dose.<br/>If NORVIR is used with another protease inhibitor, see the complete prescribing information for the concomitant protease inhibitor for details on co-administration with atorvastatin and rosuvastatin.</td>
</tr>
<tr>
<td>Immunosuppressants:<br/>cyclosporine, tacrolimus, sirolimus (rapamycin)</td>
<td>↑ immunosuppressants</td>
<td>Therapeutic concentration monitoring is recommended for immunosuppressant agents when co-administered with ritonavir.</td>
</tr>
<tr>
<td>Inhaled or Intranasal<br/> Steroid: e.g.<br/>fluticasone<br/>budesonide</td>
<td>↑ glucocorticoids</td>
<td>
<paragraph id="p453441291426806781">Concomitant use of ritonavir and fluticasone or other glucocorticoids that are metabolized by CYP3A is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects. Concomitant use may result in increased steroid concentrations and reduced serum cortisol concentrations.<br/>
<br/>
</paragraph>
<paragraph id="p453461291426806793">Systemic corticosteroid effects including Cushing's syndrome and adrenal suppression have been reported during postmarketing use in patients when ritonavir has been coadministered with fluticasone propionate or budesonide.</paragraph>
</td>
</tr>
<tr>
<td>Long-acting beta-adrenoceptor agonist: salmeterol	</td>
<td>↑ salmeterol	</td>
<td>Concurrent administration of salmeterol and ritonavir is not recommended. The combination may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations and sinus tachycardia.</td>
</tr>
<tr>
<td>Narcotic Analgesic:<br/>methadone<br/>fentanyl</td>
<td>↓ methadone<br/>↑ fentanyl</td>
<td>
<paragraph id="p455801291426808639">Dosage increase of methadone may be considered.<br/>Concentrations of fentanyl are expected to increase. Careful monitoring of therapeutic and adverse effects (including potentially fatal respiratory depression) is recommended when fentanyl is concomitantly administered with NORVIR.</paragraph>
</td>
</tr>
<tr>
<td>Neuroleptics:<br/>perphenazine, risperidone, thioridazine</td>
<td>↑ neuroleptics</td>
<td>A dose decrease may be needed for these drugs when co-administered with ritonavir.</td>
</tr>
<tr>
<td>Oral Contraceptives or Patch Contraceptives:<br/>  ethinyl estradiol</td>
<td>↓ ethinyl estradiol</td>
<td>Alternate methods of contraception should be considered.</td>
</tr>
<tr>
<td>PDE5 Inhibitors:<br/>avanafil<br/> sildenafil, <br/>tadalafil,<br/>vardenafil</td>
<td>↑ avanafil<br/>↑ sildenafil<br/>↑ tadalafil<br/>↑ vardenafil</td>
<td>
<paragraph id="p171665291426806865">Do not use ritonavir with avanafil because a safe and effective avanafil dosage regimen has not been established. <br/>
<br/>
</paragraph>
<paragraph id="p171525291426806872">Particular caution should be used when prescribing sildenafil, tadalafil or vardenafil in patients receiving ritonavir. Coadministration of ritonavir with these drugs is expected to substantially increase their concentrations and may result in an increase in PDE5 inhibitor associated adverse events, including hypotension, syncope, visual changes, and prolonged erection.<br/>
<br/>
</paragraph>
<paragraph id="p356275291426806884">Use of PDE5 inhibitors for pulmonary arterial hypertension (PAH): <br/>
<br/>
</paragraph>
<paragraph id="p356295291426806892">Sildenafil (Revatio<sup>®</sup>) is contraindicated when used for the treatment of pulmonary arterial hypertension (PAH) because a safe and effective dose has not been established when used with ritonavir <content stylecode="italics">[see Contraindications <linkhtml href="#section_4">(4)</linkhtml>].</content>
<br/>
<br/>
</paragraph>
<paragraph id="p451055291426806905">The following dose adjustments are recommended for use of tadalafil (Adcirca<sup>TM</sup>) with ritonavir:  <br/>
<br/>
</paragraph>
<paragraph id="p453234291426806915">
<content stylecode="underline">Co-administration of ADCIRCA in patients on ritonavir:</content>
<br/>
<br/>
</paragraph>
<paragraph id="p453481291426806924">In patients receiving ritonavir for at least one week, start ADCIRCA at 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability.<br/>
<br/>
</paragraph>
<paragraph id="p453501291426806936">
<content stylecode="underline">Co-administration of ritonavir in patients on ADCIRCA:</content>
<br/>
<br/>
</paragraph>
<paragraph id="p453521291426806945">Avoid use of ADCIRCA during the initiation of ritonavir. Stop ADCIRCA at least 24 hours prior to starting ritonavir. After at least one week following the initiation of ritonavir, resume ADCIRCA at 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability.<br/>
<br/>
</paragraph>
<paragraph id="p453541291426806956">Use of PDE5 inhibitors for the treatment of erectile dysfunction: <br/>
<br/>
</paragraph>
<paragraph id="p453561291426806964">It is recommended not to exceed the following doses:</paragraph>
<list id="l192381465" listtype="unordered">
<item>Sildenafil: 25 mg every 48 hours</item>
<item>Tadalafil: 10 mg every 72 hours</item>
<item>Vardenafil: 2.5 mg every 72 hours</item>
</list>
<br/>Use with increased monitoring for adverse events.</td>
</tr>
<tr>
<td>Sedative/hypnotics:<br/>buspirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem </td>
<td>↑ sedative/hypnotics </td>
<td>A dose decrease may be needed for these drugs when co-administered with ritonavir.</td>
</tr>
<tr>
<td>Sedative/hypnotics: Parenteral midazolam<br/>
</td>
<td>↑ midazolam</td>
<td>Co-administration of oral midazolam with NORVIR is CONTRAINDICATED. Concomitant use of parenteral midazolam with NORVIR may increase plasma concentrations of midazolam. Co-administration should be done in a setting which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation. Dosage reduction for midazolam should be considered, especially if more than a single dose of midazolam is administered.</td>
</tr>
<tr>
<td>Steroids (systemic): e.g. <br/>budesonide, dexamethasone, prednisone </td>
<td>↑ glucocorticoids</td>
<td>Concomitant use of glucocorticoids that are metabolized by CYP3A is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects. Concomitant use may result in increased steroid concentrations and reduced serum cortisol concentrations. This may increase the risk for development of systemic corticosteroid effects including Cushing’s syndrome and adrenal suppression.  </td>
</tr>
<tr>
<td>Stimulant:<br/>methamphetamine</td>
<td>↑ methamphetamine</td>
<td>Use with caution. A dose decrease of methamphetamine may be needed when co-administered with ritonavir.</td>
</tr>
</tbody>
</table>